SCHEMBL18751674

SCHEMBL18751674

CC(C)(C)C(=O)Cc1ccc(CC(=O)C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.46
HPGD P15428 2/20 0.42
ELANE P08246 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
CA2 P00918 2/20 0.41
CAMK2A Q9UQM7 1/20 0.41
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CES2 O00748 1/20 0.39
AKR1B1 P15121 1/20 0.39
MAPK1 P28482 1/20 0.38
ABCC4 O15439 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16722805 0.93 ELANE (0.52) CES1HPGDELANERXRARXRB
SCHEMBL18116111 0.91 CA2 (0.56) CES1HPGDRXRARXRBRXRG
SCHEMBL8980228 0.91 CA2 (0.56) ELANECA2CAMK2AKDM4EMAPK1
SCHEMBL11389533 0.91 HPGD (0.55) CES1HPGDL3MBTL1ALDH1A1LMNA
SCHEMBL8235929 0.89 KMT2A (0.46) HPGDKDM4EL3MBTL1ALDH1A1LMNA
SCHEMBL21087159 0.89 LOXL2 (0.46) CES1CA2KDM4E
SCHEMBL1477511 0.89 L3MBTL1 (0.54) HPGDL3MBTL1ALDH1A1MAPK1LMNA
SCHEMBL14254882 0.89 KDM4E (0.54) CES1HPGDKDM4EALDH1A1HSD17B10
SCHEMBL18116103 0.89 EPHX2 (0.44) CES1HPGDCA2ALDH1A1LMNA
SCHEMBL855690 0.88 CES1 (0.63) CES1HSD11B1KDM4EL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017556-B2 Insulin receptor partial agonists MERCK SHARP & DOHME CORP. (US) 2018-07-10 US disclosed
US-20170355743-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-12-14 US disclosed
US-20170107268-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355743-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 CES1 1697/4885HPGD 3295/4885ELANE 2560/4885
US-10017556-B2 Insulin receptor partial agonists INSR, GPR119, IRS1 CES1 1697/4885HPGD 3295/4885ELANE 2560/4885
US-20170107268-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 CES1 1697/4885HPGD 3295/4885ELANE 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.